Is Relapse-Free Survival at 2-Years an Appropriate Surrogate for Overall Survival at 5-Years in EGFR-mutated Resected NSCLC?

被引：0
|
作者：
Garcia, M. [1 ]
Schmid, S. [1 ]
Hueniken, K. [1 ]
Zhan, L. [1 ]
Balaratnam, K. [1 ]
Khan, K. [1 ]
Fares, A. [2 ]
Chan, S. [1 ]
Smith, E. [1 ]
Aggarwal, R. [1 ]
Brown, M. C. [1 ]
Patel, D. [1 ]
Sacher, A. [1 ]
Bradbury, P. [1 ]
Shepherd, F. A. [1 ]
Leighl, N. [1 ]
Liu, G. [1 ]
机构：
[1] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] Famerp, Ctr Oncol Hosp Base, Sao Jose Do Rio Preto, SP, Brazil
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期
关键词：
NSCLC; EGFR;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P48.05
引用
收藏
页码：S1107 / S1108
页数：2
相关论文
共 50 条
  • [1] Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
    Tsuboi, Masahiro
    Herbst, Roy S.
    John, Thomas
    Kato, Terufumi
    Majem, Margarita
    Grohe, Christian
    Wang, Jie
    Goldman, Jonathan W.
    Lu, Shun
    Su, Wu-Chou
    de Marinis, Filippo
    Shepherd, Frances A.
    Lee, Ki Hyeong
    Le, Nhieu Thi
    Dechaphunkul, Arunee
    Kowalski, Dariusz
    Poole, Lynne
    Bolanos, Ana
    Rukazenkov, Yuri
    Wu, Yi-Long
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (02): : 137 - 147
  • [2] Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
    Masahiro Tsuboi
    Roy S. Herbst
    Thomas John
    Terufumi Kato
    Margarita Majem
    Christian Grohé
    Jie Wang
    Jonathan W. Goldman
    Shun Lu
    Filippo de Marinis
    Frances A. Shepherd
    Ki Hyeong Lee
    Nhieu Thi Le
    Arunee Dechaphunkul
    Dariusz Kowalski
    Laura Bonanno
    Manuel Dómine
    Lynne Poole
    Ana Bolanos
    Yuri Rukazenkov
    Yi-Long Wu
    Targeted Oncology, 2024, 19 : 131 - 134
  • [3] Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
    Tsuboi, Masahiro
    Herbst, Roy S.
    John, Thomas
    Kato, Terufumi
    Majem, Margarita
    Grohe, Christian
    Wang, Jie
    Goldman, Jonathan W.
    Lu, Shun
    de Marinis, Filippo
    Shepherd, Frances A.
    Lee, Ki Hyeong
    Le, Nhieu Thi
    Dechaphunkul, Arunee
    Kowalski, Dariusz
    Bonanno, Laura
    Domine, Manuel
    Poole, Lynne
    Bolanos, Ana
    Rukazenkov, Yuri
    Wu, Yi-Long
    TARGETED ONCOLOGY, 2024, 19 (02) : 131 - 134
  • [4] Osimertinib also improves overall survival in EGFR-mutated NSCLC
    Lichert, Frank
    PNEUMOLOGIE, 2024, 78 (03): : 143 - 143
  • [5] Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
    Ramalingam, S. S.
    Vansteenkiste, J.
    Planchard, D.
    Cho, B. C.
    Gray, J. E.
    Ohe, Y.
    Zhou, C.
    Reungwetwattana, T.
    Cheng, Y.
    Chewaskulyong, B.
    Shah, R.
    Cobo, M.
    Lee, K. H.
    Cheema, P.
    Tiseo, M.
    John, T.
    Lin, M-C
    Imamura, F.
    Kurata, T.
    Todd, A.
    Hodge, R.
    Saggese, M.
    Rukazenkov, Y.
    Soria, J-C
    Boyer, Michael
    Lee, Chee
    Hughes, Brett
    O'Byrne, Kenneth
    Briggs, Peter
    Milward, Michael
    John, Thomas
    Demedts, Ingel
    Vansteenkiste, Johan
    Bustin, Frederique
    Barrios, Carlos Henrique
    Timcheva, Constanta
    Butts, Charles
    Goss, Glenwood
    Juergens, Rosalyn
    Leighl, Natasha
    Cheng, Susanna
    Burkes, Ronald
    Zhou, Caicun
    Zhang, Helong
    Shu, Yongqian
    Cheng, Ying
    Zhou, Qing
    Li, Wei
    Feng, Guosheng
    He, Yong
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (01): : 41 - 50
  • [6] 5-years conditional disease free survival and overall survival for breast cancer patients in South Korea
    Ahn, J. H.
    Yu, J. H.
    Nam, S. J.
    Lee, J. E.
    Kim, S. W.
    Lee, S. K.
    Chae, B. J.
    Ryu, J. M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [7] Evaluating the potential of relapse-free survival as a surrogate for overall survival in the adjuvant therapy of melanoma with checkpoint inhibitors
    Coart, Elisabeth
    Suciu, Stefan
    Squifflet, Pierre
    Saad, Everardo D.
    Moshyk, Andriy
    de Schaetzen, Gaetan
    Buyse, Marc
    Weber, Jeffrey S.
    Eggermont, Alexander
    Kotapati, Srividya
    EUROPEAN JOURNAL OF CANCER, 2020, 137 : 171 - 174
  • [8] Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy
    Suciu, Stefan
    Eggermont, Alexander M. M.
    Lorigan, Paul
    Kirkwood, John M.
    Markovic, Svetomir N.
    Garbe, Claus
    Cameron, David
    Kotapati, Srividya
    Chen, Tai-Tsang
    Wheatley, Keith
    Ives, Natalie
    de Schaetzen, Gaetan
    Efendi, Achmad
    Buyse, Marc
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2018, 110 (01): : 87 - 96
  • [9] The RESECT study: Factors associated with overall survival (OS) and relapse-free survival (RFS) among patients with stages I-III resected NSCLC without known EGFR mutations.
    Gray, Jhanelle Elaine
    Salomonsen, Rachel
    Georgoulia, Nefeli
    Perez, Ignacio Diaz
    Wang, Alice
    Cai, Ling
    Wetherill, Graham
    Xiao, Yang
    Fielden, Claire
    Altorki, Nasser K.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] RELAY: final overall survival with erlotinib plus ramucirumab or placebo in untreated, EGFR-mutated metastatic NSCLC (mNSCLC)
    Nakagawa, K.
    Garon, E. B.
    Nishio, M.
    Seto, T.
    Nishio, K.
    Kasahara, K.
    Nishino, K.
    Satouchi, M.
    Yoh, K.
    Hayashi, H.
    Enatsu, S.
    Frimodt-Moller, B.
    Matsui, T.
    Varughese, S. C.
    Visseren-Grul, C.
    Reck, M.
    ANNALS OF ONCOLOGY, 2024, 35 : S1313 - S1313
12345